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Bacterial derived lipoproteins constitute potent macrophage activators in vivo and are eﬀective
stimuli, enhancing the immune response especially with respect to low or non-immunogenic
compounds. In the present study we have prepared branched lipopeptide constructs in which
diﬀerent (B- and T-cell) epitopes of Herpes simplex virus type 1, derived from glycoproteins B
(gB) and D (gD), are linked to a synthetic lipid core. The ability of the lipid core peptide (LCP)
constructs (LCP-gB and LCP-gD) to induce cytokine expression and activate the mitogen-
activated protein kinase cascade has been evaluated and compared with the behaviour of the
isolated epitopes and the lipid core. In this respect, the use of LCP technology coupled with the
use of three diﬀerent gB or gD peptide epitopes in the same branched constructs could represent
an interesting approach in order to obtain eﬃcient delivery systems in the development of a
synthetic multiepitopic vaccine for the prevention of viral infections.
1. Introduction
Subunit protein or peptide vaccines are becoming increasingly
popular due to their safety, lack of side eﬀects and easy
production.1,2 However, a major disadvantage with using
peptides as vaccines is that they do not generate suﬃcient
immune response. This is because peptide haptens do not
trigger the pattern recognition receptors and do not activate
the phagocytic cells. Without activation of the enhanced antigen
presenting cells (APC), the T and B lymphocytes are not
activated and a productive immune response is not initiated.
As a consequence, a critical issue in the development of
synthetic peptide vaccines is that, despite containing extremely
pure antigens, they tend to be poorly immunogenic compared
to live attenuated vaccines.3,4 Therefore, an important step in
the development of epitope-based vaccines is the identiﬁcation
of a safe, eﬃcient, and adjuvant-free antigen delivery system to
achieve enhanced antigen presenting cells response.2
Conventional vaccine formulations to be administered in
animal models require the use of adjuvants such as complete
Freund’s adjuvant (CFA) or others unsuitable for human use
due to their high toxicity,5 while current vaccines licensed for
human use mainly contain alum-based adjuvants.6 An alter-
native strategy to overcome the use of toxic adjuvants is to
exploit novel self-adjuvating delivery systems. The technology
based on lipid core peptide (LCP) constructs represents a
potentially safe option for vaccine delivery in humans and
gives the possibility to incorporate multiple copies of diﬀerent
glycoprotein peptides.7
The LCP system has been described by Moyle and Toth8 in
which lipoamino acids are coupled to a polylysine core con-
taining up to two diﬀerent peptides of interest at deﬁned
positions. It is designed to incorporate the antigen, adjuvant
and carrier moieties all in the same molecular entity.9,10 LCP
can be easily synthesized in a single reaction vessel, by step-wise
solid-phase methods, without isolating any of the intermediates.
The LCP system essentially combines lipidic adjuvant, carrier
and multiple peptide epitope. When covalently linked to a
peptide, pam3cys lipopeptide compounds were found to be
potent immunogens with self-adjuvating properties, eliciting
humoral and cellular responses, irrespective of the route of
administration.11–14 Most importantly, lipopeptide constructs
represent potent safe vaccines for human applications.15 The
technology has proven eﬀective in a number of experimental
models. In fact, LCP-based vaccine candidates incorporating
domains of Chlamydia trachomatis outer membrane protein
and viral peptides from foot-and-mouth disease virus were
immunogenic and resulted in the induction of peptide anti-
bodies in the absence of any additional adjuvant.16,17 Further-
more, LCP formulation incorporating epitopes from the group A
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streptococci (GAS) were tested in murine parental immunization
and GAS challenge models. Immunization led to the induction of
high-titer GAS peptide-speciﬁc serum IgG antibody responses and
the induction of high opsonic antibodies. Moreover, mice were
protected from GAS infection following challenge.10,18–22 Another
LCP formulation was tested by Haro et al. They analysed the
immunogenic properties of a tetrameric heterogeneous palmitoyl-
derivatised MAP containing two HAV peptide sequences,
VP1(11^25) and VP3(102^121), in immunised rabbits.23
For the rational design of synthetic vaccines, a potential
immunogen must contain appropriate helper T cell and B cell
determinants to elicit a strong and relevant immune response. Tam
and co-workers24 have described an innovative method which
involves the synthesis of a multiple antigenic peptide in which
multiple copies of the same peptide are assembled on a lysine core
through the a and e amino groups. The availability of orthogonally
protected lysine derivatives allows the synthesis of peptide con-
taining diﬀerent determinants with a potential use in the design of
multivalent vaccines incorporating diﬀerent B and T cell deter-
minants. Furthermore, innovative synthetic strategies have been
developed by Andreu et al. to prepare a multivalent lipopeptide
dendrimer incorporating four copies of disulﬁde-mediated cyclic
epitopes which has been successfully used in an experimental
vaccination trial against foot-and-mouth disease virus.25
Branched synthetic peptide constructs were found to be
superior in eliciting antibody when compared to the same
determinants assembled in a linear conformation.26 Moreover,
formulation of an eﬀective immunogen that could elicit a potent
immune response should incorporate both B cell epitopes that
mimic the three-dimensional conformation of the antigen and
T cell epitopes resulting from the processed protein, on the same
carrier that links the major histocompatibility complex (MHC)
with the T cell receptor. Identiﬁcation of the T and B-cell
epitopes is crucial for the development of eﬀective vaccines
against infectious agents and diﬀerent tools are used for their
identiﬁcation. The TEPITOPE prediction software has been
shown to be a useful tool in the identiﬁcation of candidate T cell
epitopes in many protein antigen, allowing considerable
reduction of the number of peptides to be assayed in vitro;
moreover, it has been successfully employed to identify
HLA-DR ligands derived from tumors,27,28 endogenous protein
involved in autoimmune diseases,29 viral protein 16 (VP16) of
HSV-230 and gD of HSV-1.31 B cell epitopes are located on the
surface of proteins usually near g-turns and were identiﬁed
using the Chou–Fasman and PHD (Proﬁle network prediction
HeiDelberg) prediction methods;32,33 revealing the hydrophilic
sequences with unordered structure or g-turn.
HSV-1 infections are commonly worldwide between 60%
and 90% of the adult population in Europe and USA having
HSV-1 antibodies.34 The prevalence of HSV-2 among adults
varies between 20% and 90%, depending upon the country,
region within the country and subgroups of population.34
HSV infections are therefore extremely common and cause
a wide range of symptoms, from non-apparent to life-
threatening diseases, including genital herpes, orolabial infec-
tions (e.g. gingivostomatitis, labialis, pharyngitis), cutaneous
infections (e.g. whitlow, herpes gladiatorum), ocular infections,
neonatal herpes, herpes encephalitis, disseminated infection and
erythema multiforme.35 Recurrent genital and orolabial HSV
infections cause severe health problems and psychological distress
requiring health care. HSV usually initiates infection at the
mucosal membrane surface or through small lesions in the skin.
During primary infection, the virus replicates at a local site,
spreads to and up the weakened nerve, replicates in the dorsal
root or trigeminal ganglia and returns to infect the skin along the
dermatome. In addition, HSV establishes a latent infection of the
neuron, capable of being reactivated by stress, thereby causing
recurrent disease.36,37 Great eﬀort has been devoted to the
development of an eﬀective herpes vaccine that could help control
this epidemic, through the identiﬁcation of protective epitopes
and development of an eﬀective and safe immunization strategy.
The immune response is the most important defence against
HSV infection. Several pieces of evidence, in both animal and
human models, suggest that CD8+ T cells play a major role in
anti-herpes virus immunity.38 While CD8+ T cells are useful
eﬀectors in the clearance of herpes infections, CD4+ T cells
are required to help prime and sustain antiviral CD8+ T-cell
immunity.39 Consequently, an immunogenic formulation
should be targeted towards inducing both CD4+ and CD8+
T-cell populations. Possible T and B-cell epitopes were chosen
analyzing HSV glycoproteins B and D with several secondary
structure prediction methods.
Among the advantages of an epitope based vaccine against a
whole protein vaccine is the possibility of including multiple
immunodominant and subdominant epitopes and thus eliciting
superior responses. In this study, gB and gD, being the two
major targets of HSV-1 immune clearance mechanisms, have
been selected and analysed to choose candidate antigens.
In this study we have explored the potential of LCP technology
to develop a novel self-adjuvating HSV-1 multi-antigen com-
ponent vaccine delivery system, and tested the hypothesis that
diﬀerent HSV-1 gB and gD epitopes, linked to the lipid core,
would stimulate cytokine production and activate the MAPK
cascades, pointing to the application of this system in human
vaccine development against HSV infection.
2. Materials and methods
2.1. Reagents
All N-Fmoc-amino acid derivatives, the HOBt, PyBop, HATU
activants, Boc-Gly-PAM resin and 2-chlorotritylchloride resin
were purchased from Inbios (Napoli, Italy). All other chemicals
were commercially available at Sigma-Aldrich (Milano, Italy)
and were used as received unless otherwise stated. RPMI 1640,
glutamine, penicillin and streptomycin were purchased from
Gibco Life Technologies (Grand Island, NY). Fetal calf serum
(FCS) containingo0.01 endotoxin U mL1 was obtained from
HyClone Laboratories (Logan, UT).
The FACE kit for the analysis of kinase phosphorylation
was purchased from Active Motif (Carlsbad, CA). A cytokine
enzyme-linked immunosorbent assay kit was obtained from
R. . .D Systems (Minneapolis, MN, USA). A LAL gel-clot
assay was purchased from PBI International (Milan, Italy).
2.2. T and B-cell epitope prediction
The sequences of gB and gD were subjected to HLA-DR
ligand prediction by the TEPITOPE software to identify
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promiscuous HLA-DR ligands. TEPITOPE is based on
25 virtual matrices that cover a signiﬁcant part of human class II
peptide binding speciﬁcity. The TEPITOPE prediction threshold
was set at 2% and picked peptide sequences predicted to bind
at least four of the seven most common HLA-DR alleles
(DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701,
DRB1*0801, DRB1*1101, DRB1*1501) were picked. The
peptides were chosen based on their predicted binding as well
as the degree of similarity between diﬀerent strains and were
synthesized according to the sequence of HSV-1. A peptide
present in several strains but showing poor prediction of
promiscuous binding was used as a non-promiscuous control.
For B-cell epitope prediction, the sequences of gB and gD
were subjected to two diﬀerent secondary structure prediction
methods: the Chou–Fasman algorithm and the PHD method.
The Chou–Fasman algorithm predicts the a-helix, b-sheet and
other secondary structure based on the occurrence frequency
of 20 amino acids in diﬀerent protein conformations.40,41
Predictive values were calculated for each type of secondary
structure. To calculate these values, the frequency of amino
acid j in structure k is divided by the frequency of all the
residues in structure k; we obtain primary structural para-
meters Pa and Pb that range roughly from 0.5 to 1.5 for the
20 amino acids. The algorithm uses the following set of rules to
predict protein secondary structure. The sequences are ﬁrst
scanned for small fragments of residues which have a high
probability of being the nucleation of a certain type of
secondary structure. For a-helices, the core is predicted when
four of six residues have a probability >1.03 and Pa > Pb.
For b-strands, three of ﬁve residues with the probability >1.00
and Pb > Pa predict a nucleation. The nucleations are
extended along the sequence in each direction until the average
predictive value for four residues drops below 1 for a-helix
(1.05 for b-sheets). If both helix and strand are predicted in a
certain region (overlapped region), the secondary structure
conformation with higher average propensities is predicted.
The PHDmethod uses a neural network algorithm trained and
tested on a database of 24 representative protein chains of
known structure. Multiple sequence alignments are used as
input to a neural network. At the training stage, a database of
protein families aligned to proteins of known structure is used.
At the prediction stage, the database of sequences is scanned
for all homologues of the protein to be predicted, and the
family proﬁle of amino acid frequencies at each alignment
position is fed into the network. The input signal is propagated
through a network with one input, one hidden, and one output
layer. The output layer has three units corresponding to the
three secondary-structure states, helix, b-strand, and ‘‘loop’’.
2.3. Peptide synthesis
All six peptides (two T-cell epitopes and one B epitope for
each glycoprotein), fully protected on the amino acid side
chains, were synthesized by solid-phase methodology on a
2-chlorotritylchloride resin (1.25 mmol g1; 1.00 g) using the
Fmoc strategy. The resin was swelled in DCM for 30 min and
the ﬁrst amino acid was coupled by adding 1-fold molar excess
of Fmoc protected amino acid, mixed with 4-fold molar excess
of DIEA in DCM. The suspension was stirred at room
temperature for 2 h, then the resin was washed twice with a
mixture of DCM/MeOH/DIEA (17/2/1), twice with DCM and
ﬁnally swelled in DMF. Fmoc was removed using 20%
piperidine in DMF. UV-vis measurements of free Fmoc
absorption at 301 nm were performed in order to determine
the amount of linked amino acid, and therefore the synthesis
scale. For all six peptides the synthesis scale was in the
0.45–0.55 mmolar range.
The other amino acids were sequentially coupled by adding
2-fold molar excess of each Fmoc protected amino acid, mixed
with equimolar amounts of HOBt, PyBop and 2-fold molar
excess of DIEA in DMF. On the amino terminus of gB493–509,
gB577–599, gD119–140, gD215–234, Boc protected glycine was
added in order to obtain Boc protected peptides. The coupling
reaction proceeded at room temperature for 2 h under stirring,
and was monitored with the Kaiser ninhydrin test. Unreacted
amino groups were capped using a mixture of DMF/acetic
anhydride/pyridine (91.3/4.7/4). The fully protected peptides
were cleaved from the solid support by suspending the resin in
a mixture of TFA/(TIS)/DCM (1/5/94) for 2 min; then the
solution (10.0 mL) was ﬁltered into a ﬂask containing 10%
pyridine in MeOH (2 mL). This cleavage procedure was
repeated up to 10 times, the ﬁltrates were combined and
evaporated under reduced pressure to 5% of the initial
volume. The crude products were precipitated by adding
cold water, and puriﬁed by RP-HPLC on a Shimadzu 8A
apparatus equipped with an UV Shimadzu detector using a
Phenomenex C18 column (Torrance, CA, USA) 22  250 mm,
eluted with the H2O–0.1% TFA (A) and CH3CN–0.1% TFA
(B) mixture; a two step gradient was used: from 60% to 80%
of B in 10 min and from 80% to 95% of B in 15 min with a
ﬂow rate of 20 mL min1. The puriﬁed peptides were char-
acterized by LC-ESI-MS using a Finnigan Surveyor MSQ
single quadrupole electrospray ionisation mass spectrometer
coupled with a Finnigan Surveyor HPLC (Finnigan/Thermo
Electron Corporation San Jose, CA, USA) or by MALDI-TOF
on a MALDI-TOF Voyager-DE Perseptive Biosystem
(Framingham, MA). The six peptides fully deprotected on
the amino acid side chains were also obtained by cleaving from
the resin with TFA/TIS/H2O (95.5/2.5/2) mixture and HPLC
puriﬁcation. The molecular masses for each peptide, in the
protected or deprotected form, are reported in Table 1.
2.4. Synthesis of LCP constructs
Synthesis of the two LPC systems was carried out using solid-
phase methodology with a combination of Fmoc and Boc
based strategies. Pre-loaded Boc-Gly-PAM resin (1 mmol) was
used. The ﬁrst ﬁve residues starting from the C-terminus (two
residues of Boc–C12–OH (Boc–NH2CH[(CH2)9CH3]COOH)
one residue of Boc-Gly-OH, one residue of Boc–C12–OH and
one residue of Fmoc-Lys(Mtt)-OH) were sequentially coupled
using the following coupling procedure: single coupling, with
the addition of 2 equivalents of protected amino acids activated
with 2 equivalents of HATU and 4 equivalents of DIEA in the
DCM–DMFmixture, and stirring for 30 min. Boc deprotection
steps were performed with 33% TFA/DCM (2 + 20 min). To
obtain the branched construct, Fmoc and Mtt protecting
groups from the lysine residue were selectively removed,
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and Fmoc-Lys(Dde)-OH and Fmoc-Lys(Mtt)-OH sequen-
tially coupled on the alpha and epsilon free amino functions.
In particular, the Fmoc protecting group was removed using a
solution of 20% piperidine in DMF and Fmoc-Lys(Dde)-OH
was coupled to the alpha amino function. After removal of the
Mtt-protecting group, using a mixture of TFA/TIS/DCM (1/5/94),
the Fmoc-Lys(Mtt)-OH was assembled as described above. After
removal of Fmoc and the Dde amino protecting group, a small
quantity of dried Lys3-LCP-resin was treated with TFA (1 mL)
and TIS (3%) and the mixture stirred at room temperature for
5 min. The mixture was then cooled in an ice bath and TFMSA
(100 mL) added dropwise with stirring. The ﬂask was sealed with
a stopper and the mixture stirred at room temperature for 2 h.
The volume was reduced under vacuum and the mixture was
cooled in an ice slush bath. The crude product was precipitated
adding diethyl ether. The liquid phase was removed by ﬁltration,
and the solid dissolved in 50% (v/v) water–acetonitrile. The
crude product was recollected after lyophilization and puriﬁed
by RP-HPLC (from 5% to 70% of B in 30 min with a ﬂow
rate of 20 mL min1) on a semipreparative C18 column and
characterized by MALDI-TOF (Mw = 1101).
The branched construct with three diﬀerent peptides was
obtained using the three orthogonal amino protection groups:
Fmoc, Mtt and Dde. The Fmoc-deprotection strategy
involved treatment of the protected peptide-resin with 2%
DBU/2% piperidine/NMP (5 min), followed by another 5 min
treatment with 20% (v/v) piperidine in NMP; theMtt protecting
group was removed using a mixture of TFA/TIS/DCM (1/5/94);
while the Dde protecting group was removed using 0.90 mmol
of NH2OHHCl and 0.675 mmol of imidazole in 2.5 mL of
NMP. In detail, 60 mg of Lys3-LCP-resin (30 mmol) were
suspended in DMF and the Dde protecting group was
removed as above. Two equivalents of the ﬁrst fully protected
peptide (60 mmol), with a Boc protecting group on the
N-terminus, was coupled using the same excess of HATU
and 4 equivalents of DIEA. After removal of Mtt-protecting
groups, the second peptide (60 mmol) was coupled, as
described above, with the appropriate protecting groups on
the side chains of the amino acids and the Boc-protecting
group on the N-terminus. The third peptide (120 mmol) was
coupled on the two a amino groups initially protected with
the Fmoc group. Following synthesis, the constructs were
removed from the resin by TFMSA cleavage as previously
described. The crude constructs were puriﬁed by HPLC (from
5% to 70% of B in 30 min with a ﬂow rate of 20 mL min1)
on reverse phase (yields LCP-gB 30%, LCP-gD 32%). ESI
mass-spectroscopy conﬁrmed the product identity:
Mw(LCP-gB) = 7698.6 amu; [M + 5H
+]/5 = 1540 amu;
[M + 6H+ + Na+]/7 = 1103.8 amu; [M + 8H+]/8 =
963.4 amu; [M + 9H+]/9 = 857.1 amu. (MALDI TOF
7699 amu). HPLC tr 19.18.
Mw(LCP-gD) = 7654 amu; [M + 6H
+]/6 = 1277.1 amu;
[M + 8H+]/8 = 957.9 amu; [M + 9H+]/9 = 851.6 amu.
(MALDI TOF 7654 amu). HPLC tr 21.88.
2.5. Cell lines
U937 monocytes (ATCC CRL-1593.2) were grown at 37 1C
in 5% CO2 in RPMI 1640 supplemented with 10% heat-
inactivated FCS, glutamine (2 mM), penicillin (100 U mL1),
and streptomycin (100 UmL1) and diﬀerentiated as previously
described.42 RAW 264.7 cells, a murine macrophage line, were
obtained from ATCC (TIB-71t). Cells were cultivated in
RPMI 1640 supplemented with 10% heat-inactivated fetal
bovine serum, 2 mM L-glutamine, 100 U mL1 penicillin,
and 0.1 mg mL1 streptomycin. The cells were maintained at
37 1C with 5% CO2 in a humidiﬁed incubator.
43
Before treatment of the cells, the serum concentration was
reduced to 5% for 24 h at 37 1C and then further reduced to
serum free media for at least 10–12 h. This should almost
eliminate interference from serum factors in the phosphoryla-
tion state of the proteins in the signalling cascade.
2.6. Analysis of kinase phosphorylation
U937 diﬀerentiated cells and RAW 264.7 cells (1.2  105 cells
per well) were grown in 96-well plates in accordance with the
manufacture’s protocol so that they will be approximately
80% conﬂuent at the time of stimulation. Cells were stimu-
lated to induce the pathway of interest at 37 1C with 10 mM of
each single peptide, 2.5 mM of each LCP construct and 2.5 mM
of Lys3-LCP, LCP alone, and Lys3-LCP with non-covalently
attached gB and gD peptides (LCP/gB and LCP/gD) for
10 min. The optimal time of stimulation and amount of stimuli
used in all assays were determined in preliminary experiments
(data not shown). Following stimulation, the cells were rapidly
ﬁxed to preserve activation-speciﬁc protein modiﬁcations.
Each well was then incubated with a primary antibody that
recognized either phosphorylated or total p38, JNK and ERK
1/2. Subsequent incubation with secondary HRP-conjugated
antibody and developing solution has provided a quantiﬁed
colorimetric readout. Phosphorylated p38, JNK and ERK1/2
detection was performed according to the manufacture’s
instructions.
Table 1 Amino acid sequences of the T-and B-cell epitopes and characterization data of the six synthesized peptides. Found molecular weights
are reported for fully protected (f.p.) and fully deprotected (f.d.) peptides. HPLC retention times are reported for the six fully deprotected peptides
Protein fragment Amino acid sequences Epitope Mw (f.d. peptides) Mw (f.p. peptides) Rt (min) (f.d. peptides) Yield (%)
gB308–316 HTEHTSYAA B m/z 1018 m/z 1527 8.59 55
[Gly]gB577–599 GAADNVIVQNSMRISSRPGACYSR T m/2z 1277 m/z 3765 12.03 56
m/3z 851
[Gly]gB493–509 GERIKTTSSIEFARLQFT T m/2z 1042 m/z 3096 12.39 60
m/3z 695
gD301–309 SALLEDPVG B m/z 899 m/z 1293 9.53 60
[Gly]gD119–140 GNLTIAWFRMGGNCAIPITVMEY T m/z 2556 m/z 3245 15.10 54
[Gly]gD215–234 GKYALPLRIPPSACLSPQAYQ T m/z 2271 m/z 2957 21.50 57
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2.7. Treatment of U937 and RAW 264.7 cells with speciﬁc
MAPK inhibitors
In some experiments, before exposure to stimuli, U937 and
RAW 264.7 cells were pretreated with diﬀerent inhibitors:
4-(4-ﬂuorophenyl)-5-(4-pyridyl) 1H-imidazole (SB203580;
Calbiochem-Novabiochem GmbH, Schwalbach, Germany)
(10 mM for 1 h), a speciﬁc inhibitor of the p38 pathway;44
20-amino-30-methoxyﬂavone (PD-098059; New England
Biolabs, Inc.) (100 mM for 1 h) a highly selective inhibitor
that blocks ERK1/2 activation by speciﬁcally inhibiting
MEK1, a kinase that catalyses ERK1/2 phosphorylation;45
JNKinhibitor-1 (L-JNKI1; Alexis Biochemicals, San Diego,
CA) (1 mM for 1 h), a peptide that speciﬁcally binds to and
inhibits JNK activity.46 The inhibitors were prepared in
dimethyl sulfoxide at a ﬁnal concentration of 0.1% (v/v).
2.8. Enzyme-linked immunosorbent assay for cytokine
Culture supernatants for ELISAwere collected after 24 h following
incubation of U937 and RAW 264.7 cells (3  106 cells per mL)
with stimuli. The optimal concentrations of stimuli (10 mM of
each peptide, 2.5 mM of each construct and 2.5 mM of the
following controls: Lys3-LCP, LCP, LCP/gB and LCP/gD)
and time point of stimulation have been selected using preli-
minary experiments (data not shown). After incubation, the
samples were centrifuged at 1800 rpm at 4 1C for 10 min, and
the supernatants were collected and stored at 70 1C. IL-6,
IL-8 or the functional homolog of human IL-8, mouse macro-
phage inﬂammatory peptide-2 (MIP-2), and TNF-a were
analyzed. Cytokine release was measured according to the
manufacturer’s recommendations. The assay employs an anti-
body speciﬁc for each cytokine coated on a 96-well plate.
Standards, samples and biotinylated anti IL-6, IL-8 or MIP-2
and TNF-a were pipetted into the wells and cytokine present
in the samples was captured by the antibody immobilized to
the wells and by the biotinylated speciﬁc detection antibody.
Standard and sample dilutions were added in duplicate wells
to each plate. All analyses were performed at least three times
for each individual cell-stimulation assay.
2.9. Endotoxin contamination
All solutions and peptide preparations used in our experiments
were tested for the presence of endotoxin using a LAL assay as
described by Yin and others.47 The lower detection limit of
this assay was 0.1 EU mL1.
2.10. LDH assay
LDH assay was carried out according to the manufacturer’s
instructions using a cytotoxicity detection kit (Roche Diagnostic
SpA, Milano, Italy). LDH is a stable cytoplasmic enzyme
present in all cells and is rapidly released into cell culture
supernatant when the plasma membrane is damaged. LDH
activity was determined by a coupled enzymatic reaction
whereby the INT was reduced to formazan. An increase in
the number of dead or damaged cells resulted in an increase in
LDH activity in the culture supernatant. The amount of LDH
shows that treated and untreated cells are healthy.
2.11. Statistical analysis
Each experiment was performed in triplicate. The data are
expressed as the mean  SEM and were analyzed using
Student’s t test. Results were considered to be statistically
signiﬁcant at P values of r0.01.
3. Results
3.1. Identiﬁcation of potential T- and B-cell epitopes
(of HSV-1 gB and gD)
In order to choose the possible T- and B-cell epitopes to
conjugate to the lipid core, HSV-1 gB and gD have been analysed
with several prediction programs and the data obtained have
been compared. The identiﬁcation of T-cell epitopes is crucial for
the development of eﬀective vaccines. As T-cell epitopes only
encompass a very small region of a complex protein, the mapping
of the dominant T-cell epitopes of an antigen is a diﬃcult
procedure. To identify the possible T-cell epitopes, in this study
the TEPITOPE prediction program has been used.
The goal of T-cell epitope prediction is to accurately identify
peptide sequences within any protein that, in the context of a
deﬁned MHCmolecule, will elicit desired T-cell responses. For
peptide vaccination, these epitopes should ideally be dominant
and promiscuous, so that they are recognised by most indivi-
duals within an outbreed population. We investigated whether
promiscuous HLA-DL ligands could be identiﬁed in the
sequences of the HSV-1 glycoproteins gB and gD. We used
a stringent threshold setting, which was proven to be eﬀective
in predicting up to 80% of an in vitro-selected peptide reper-
toire. The selected T-cell epitopes for each glycoprotein are
reported in Table 1. We selected two peptides for each
glycoprotein with a strong prediction of promiscuous binding
to HLA-DR. To the nonamer selected by the T epitope as the
core HLA-binding motif, two amino acids were added at the
terminal moieties to increase the eﬃcacy of the in vitro peptide
presentation to the CD4+ T cells. When there was the super-
imposition of more than one hypothetical HLA-binding
frame, longer sequences were synthesized. Moreover, the
addition of polar amino acids at the C or N terminus was
performed in order to have soluble peptides.
In particular, with our stringent threshold, we selected
two peptides for gD (i.e. gD119–140 and gD215–234); both
belonging to the external N-terminal portion of gD and
mapped to nonglycosylated regions of gD. From the analysis
of glycoprotein gB with the same threshold we obtained two
overlapping epitopes which correspond to the longer peptide
gB577–599 and the other epitope gB493–509. The peptide
gB577–599 is located in Domain IV while gB493–509 is
located in Domain II both peptides being located on the
protein surface.
B-cell epitopes are located on the surface of proteins, usually
near b-turns. To identify the possible B-cell epitopes several
parameters were compared such as hydrophobicity, solvent
accessibility and the secondary structure and hydrophilic
sequences with unordered structure or b-turn were chosen.
Glycoproteins gB and gD have been analyzed by Chou–Fasman
and PHD (Proﬁle network prediction HeiDelberg) prediction
methods. These secondary structure prediction methods are
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based on the propensities of amino acid residues to form
b-strands, helices or turns.
On analyzing our results we decided to select one B epitope
for each glycoprotein and from those obtained we selected
gB308–316 and gD301–309. The peptide gB308–316 is located
in Domain I; the peptide gD301–309 is located closest on the
hydrophobic membrane anchor domain of gD. Conforma-
tional analysis of the gD301–309 (SALLEDPVG) sequence
conﬁrms the presence of a type I b-turn structure which
includes the DPVG epitope core.48 Moreover, previous studies
indicated that the gD301–309 epitope induced gD-speciﬁc
responses and also elicited an immune response that conferred
protection against lethal HSV-1 infection.49
3.2. LCP-gD and LCP-gB constructs
The chemical structures of the two LCP constructs, LCP-gD and
LCP-gB, are reported in Fig. 1, and the amino acid sequences of
the six peptides corresponding to selected T- and B-cell epitopes
for HSV-1 gB and HSV-2 gD are indicated in Table 1.
The two LCP constructs were synthesized, as shown in
Fig. 2, using solid-phase techniques based on a combination
of Fmoc and Boc strategies, orthogonal protection of the lysine
residues, and fully protected peptides, previously synthesized by
solid-phase peptide synthesis. This divergent strategy enabled
us to obtain a homogeneous product. In fact all epitopes were
preventively puriﬁed by HPLC before the lipid core coupling.
Synthesis of the lipid core system (Boc-C12-C12-Gly-C12-
Gly-PAM resin) was performed manually in solid-phase under
standard conditions by using a Boc strategy. Pre-loaded Boc-
Gly-PAM resin was used. This resin is usually the support of
choice for the preparation of branched peptides by Boc based
solid phase methodologies; it is more stable under acid conditions,
during the Boc removing cycles, than the corresponding Merriﬁeld
resin. The a-aminododecanoic acid H2N–CH[(CH2)9CH3]–COOH
(C12) was obtained as described in the literature50 and pro-
tected on the N-terminal function with the Boc group, in order
to be used in solid phase synthesis.
The three-lysine branched system was built on the lypophilic
moiety, capable of bearing four peptide molecules, as schema-
tized in Fig. 2. The construct was designed to obtain molecules
bearing three diﬀerent epitopes, therefore two of the four
peptide sequences, in each construct, are identical. This result
was achieved using three orthogonal protecting groups on the
four amine functions present on the lysine branched system.
Therefore, the synthetic approach initially required, the binding
of Fmoc-Lys(Mtt)-OH, and, secondary, the binding of Fmoc-
Lys(Mtt)-OH and Fmoc-Lys(Dde)-OH, after the sequential
Fig. 1 Chemical structure of the lipid core peptide (LCP) constructs.
Panel A shows the structure of LCP conjugated with gB peptides
(LCP-gB); panel B shows the structure of LCP conjugated with gD
peptides (LCP-gD). Peptide sequences are reported in Table 1.
Fig. 2 Synthesis scheme for the preparation of LCP-gB and LCP-gD
constructs. The branched peptide conjugates were synthesized using a
combination of Fmoc and Boc solid-phase techniques, orthogonally
protected lysine residues, and fully-protected peptides.
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removal of Fmoc and Mtt protecting groups, respectively.
Sequential cleavage of the orthogonal protecting groups
allowed the sequential coupling of the fully protected peptides
chosen to build up the branched peptide constructs.
The peptide epitopes were synthesized on 2-chlorotritylchloride
resin by Fmoc chemistry and puriﬁed in solution by HPLC
methods. On the amino terminus of gB493–509, gB577–599,
gD119–140, gD215–234, a Boc protected glycine was added in
order to obtain Boc protected peptides. The superacid-labile
resin was used to obtain fully protected peptides at the
peptide-resin cleavage step. Protected peptides were coupled
on the lysine branched lipid core bound to the resin, without
any undesired side reaction. The LCP constructs were removed
from the resin by TFMSA cleavage. The cleavage from the
PAM resin by TFMSA enabled the recovery of the LCP
constructs fully deprotected on the peptide side chains.
The two LCP constructs were puriﬁed by HPLC and their
purity and identity were conﬁrmed by analytical RP-HPLC
(ﬁgures reported in ESIw), ESI-MS spectrometry (Fig. 3A and B)
and MALDI TOF spectrometry (ﬁgures reported in ESIw).
The ﬁnal product yields were in the range of 30–40%.
Endotoxin levels of cell cultures and peptide solutions resulted
in, LAL tests, lower than 0.1 EU mL1 (data not shown).
The six single isolated peptides, the lipid core containing
only the three lysine branched sequence with the lysine amino
functions still protected (Lys3-LCP) and the non-covalent
mixtures containing Lys3-LCP and gB or gD peptides were
also prepared to be used in comparative experiments.
3.3. MAPK pathway activation
Among the most activated signal transduction pathways involved
in the immune response are the mitogen-activated protein kinase
pathways. MAPKs are a group of serine/threonine protein
kinases which can be activated by various extracellular stimuli.
MAPKs play a key role in the regulation of gene expression and
cytoplasmic activities. Three major MAPK modules exist in
mammalian species: JNK, ERK and the p38 mitogen-activated
protein kinase (p38). The activation of the terminal kinase results
in nuclear translocation and presents binding of transcription
factors resulting in the gene expression of mediators involved in
the inﬂammatory and immunological response.51
We tested the ability of the two constructs and of isolated
corresponding peptides to activate p38, JNK and ERK1/2 path-
ways in U937 and RAW 264.7 cells. Results show that the lipid
core alone (LCP), the lysine-lipid core (Lys3-LCP), the two
constructs containing the HSV peptides conjugated to the lipid
core (LCP-gB and LCP-gD) and the lysine-lipid core with non-
covalently bound peptides (LCP/gB and LCP/gD) were able to
activate all the pathways assessed, although with diﬀerent inten-
sities. Among the kinases studied, ERK1/2 was activated at higher
levels by the three constructs used. Induction was about 4–5 fold
higher compared to the single isolated peptides (Fig. 4 and 5).
3.4. Cytokines release in LCP-stimulated U937 and RAW
264.7 cells
It has been well demonstrated that lipoproteins or synthetic
lipopeptides, such as mycoplasma fermentans-derived macro-
phage-activating lipopeptide 2, a toll-like receptor 2 agonist,
stimulate both human and murine macrophages and induce
the secretion of proinﬂammatory cytokines via the activation
of MAPK pathways.52 We have therefore tested the release of
IL-6, IL-8 or MIP-2 and TNF-a by immune-responsive cells in
the form of isolated U937 and RAW 264.7 cells. The supernatant
of U937 and RAW 264.7 cell cultures was tested by ELISA for
the presence of secreted IL-6, IL-8 or MIP-2 and TNF in
response to diﬀerent lipopeptide constructs and compared with
that induced by the Lys3-LCP system alone. We also compared
the release of cytokines after stimulation with peptides with the
release obtained when stimulating cells with the lipidic constructs
containing the same peptides non-covalently attached to the
lysine-lipid core. Optimal concentrations (10 mMof each peptide;
2.5 mM of each construct; 2.5 mM of LCP; 2.5 mM of LCP/gB
and LCP/gD) and time point of stimulation have been selected
by preliminary experiments. For stimulation experiments, RAW
264.7 murine macrophage cell line and U937 human monocytic
cell line were seeded at 3  106 cells per mL density and then
treated for a 24 h period. The various treatments performed were
not toxic for the cells; in fact, they did not induce any signiﬁcant
release of LDH in the cell supernatants (data not shown).
As shown in Fig. 6, the IL-6, IL-8 or MIP-2 and TNF-a
release increased considerably when cells were treated with
LCP-gB or LCP-gD constructs compared to the production of
the same cytokines when the stimulus was represented by the
single or mixed peptides. U937 cells were more reactive to such
stimulation, and reached higher levels of cytokine production
compared to RAW 264.7 cells. We could not observe any
considerable diﬀerence between the constructs bearing gD or
gB derived epitopes. A minor increase of cytokine production
was observed in comparison with the Lys3-LCP construct
alone and with LCP/gB and LCP/gD.
3.5. Eﬀect of MAPK inhibitors on cytokine release in U937
and RAW 264.7 cells
The production of IL-6, IL-8 or MIP-2 and TNF-a is at least in
part dependent on MAPK activation. To address whether the
treatment of cells with MAPK pathways inhibitor disrupts the
axis MAPKs/gene expression of IL-6, IL-8 or MIP-2, TNF-a in
U937 and RAW 264.7 cells treated with LCP-gB/gD constructs,
we have blocked ERK1/2, JNK and p38 activation using speciﬁc
inhibitors for 1 h before treatment constructs. With the cyto-
kines produced were modestly but signiﬁcantly decreased by the
presence of speciﬁc inhibitors (Fig. 7).
The eﬀect of the ERK1/2 inhibitor PD-098059 was in percentage
the same for the release of all cytokines analysed and higher
than the eﬀect obtained using p38 and JNK speciﬁc inhibitors
in both cell lines tested. JNK speciﬁc inhibitor reduced cyto-
kine release by 20–25%, while the p38 inhibitor reduced
cytokine release to a lower level. These data suggest that both
U937 and RAW 264.7 cells produce IL-6, IL-8 or MIP-2 and
TNF-a at least partially through the activation of ERK1/2,
JNK and p38 in response to the synthesized constructs.
4. Discussion
Great eﬀort is devoted to the development of an eﬀective
herpes vaccine that could help control this epidemic, through
the identiﬁcation of protective epitopes and development of an
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eﬀective and safe immunization strategy. The focus of this study
was to explore the capacity of new LCP constructs containing
multiple copies of diﬀerent peptides, derived from HSV-1
glycoproteins f, gB or gD epitopes, to enhance the immune
Fig. 3 ESI mass spectra of: (A) LCP-gB and (B) LCP-gD constructs.
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response evaluating the cytokine production by macrophages
mediated by MAPK cascades.
Of the known HSV glycoproteins, gB and gD represent
excellent candidates for inducing a protective immunity in animal
models. The palmitoyl-tailed HSV-gB498-505–Pan HLA-DR-
binding epitope, a chimeric epitope delivered in adjuvant free
saline, induced potent virus-speciﬁc IFN-g-producing CD8+
cytotoxic T lymphocytes in H2b mice.53 Nesburn et al.49,54 have
presented a vaccine strategy that consists of ocular mucosal
delivery of peptide epitopes, selected from the glycoprotein gD
of HSV-1 mixed with synthetic immunostimulatory oligodeoxy-
nucleotides containing unmethylated CpG motifs, capable of
inducing peptide-speciﬁc and virus-neutralizing IgA/IgG in tears
as well as in serum. These studies as well as the recently identiﬁed
T-cell epitopes in gD and gB that induce potent HSV-speciﬁc
IFN-g-producing CD4+ T cells,7,55 prompted us to evaluate the
T-cell-mediated protective eﬃcacy of gB and gD epitopes linked
to a lipid core. Experimental data demonstrate that LCP
technology has the ability to develop constructs capable of
altering cell response and may be of particular advantage for
vaccine design in pathogenic immune response by HSV-1.
A multi-epitope-based herpes vaccine could thus include
several T-cell epitopes present in several diﬀerent structural
glycoproteins and regulatory proteins chosen to represent
the HLA supertypes known to provide recognition in most
individuals within an outbred population.
In this study, in order to choose potential T-cell and B-cell
epitopes, gB and gD of HSV-1 have been analysed with several
prediction programs and the data obtained have been compared.
Fig. 4 MAPK cascade activation in RAW 264.7 cells in response to a
dose of 10 mM of each single isolated peptide; 2.5 mM of each LCP
construct; 2.5 mM of LCP; 2.5 mM of Lys3-LCP; 2.5 mM of LCP/gB
and LCP/gD and at a stimulation time of 10 min. Activation of each
MAPK subfamily was determined by a quantitative assessment of
enzyme activity. The data are represented as mean  standard error.
* Pr 0.01 indicates statistically signiﬁcant diﬀerence versus untreated
cells or single/mixed peptides pretreated cells (Student’s t-test).
Fig. 5 MAPK cascade activation in U937 cells in response to a dose
of 10 mM of each peptide; 2.5 mM of each LCP construct; 2.5 mM of
LCP; 2.5 mM of Lys3-LCP 2.5 mM of LCP/gB and LCP/gD and at a
stimulation time of 10 min. Activation of each MAPK subfamily was
determined by a quantitative assessment of enzyme activity. The data
are represented as mean  standard error. * P r 0.01 indicates
statistically signiﬁcant diﬀerence versus untreated cells or single/mixed
peptides pretreated cells (Student’s t-test).
Fig. 6 IL-6, IL-8 or MIP-2 and TNF-a release after treatment with
10 mM of each peptide, 2.5 mMof each LCP construct; 2.5 mMof LCP;
2.5 mM of Lys3-LCP; 2.5 mM of LCP/gB and LCP/gD for 24 h. The
results shown are the average of three independent experiments, and
the error bars indicate the standard errors of the means. * P r 0.01
indicates statistically signiﬁcant diﬀerence versus untreated cells or
single/mixed peptides pretreated cells (Student’s t-test).
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Our experimental data demonstrate that LCP peptide technol-
ogy, associated with TEPITOPE prediction, has the ability to
alter the quality and quantity of an immune response and may
be of particular advantage for vaccine design in pathogenic
immune response by HSV-1. In recent years, a wide variety of
proteins have been used as carriers for the preparation of
synthetic peptide-based vaccines. These types of vaccines have
advantages, over traditional approaches, being selective,
chemically deﬁned and safe. Carriers are usually chosen on
the basis of size, number of reactive groups, solubility and
their potential to conceal or even eliminate the anti-peptide
response. The link between the peptide and the carrier is
chosen in such a way that the structure of the peptide is not
perturbed or shielded by the carrier. In general, peptides
incorporating epitopes in multiple copies with branched archi-
tecture are better immunogens than linear oligomers and were
found to be superior in eliciting antibodies when compared to
the same determinants assembled in a linear conformation.
Moreover, formulation of an eﬀective immunogen that could
elicit a potent immune response should incorporate B-cell
epitopes that mimic the three-dimensional conformation of the
antigen as well as T-cell epitopes resulting from the processed
protein, both on the same carrier that links the MHC with the
T-cell receptor. To achieve enhanced and prolonged humoral
and cellular immune response, potent immunogens must be also
administered in combination with external immunoadjuvants.
The LCP system containing the 2-amino-dodecanoic lipoamino
acids C12 (H2N–CH(CH2)9CH3–COOH) was found to be a potent
immunogen with self-adjuvanting properties, eliciting humoral
and cellular responses irrespective of the administration route.
This a-amino acid with its long alkyl side chain combines
structural features of lipids with those of amino acids and
peptides, and when conjugated to or incorporated into pep-
tides or drugs enhances the passage of the pharmacologically
active compounds across biological membranes. The design of
our peptide-based vaccine was meant to combine the LCP
system with branched lysines orthogonally protected with
several peptides of diﬀerent sequences and lengths. These
sequences are epitopes of glycoproteins involved in the mecha-
nism of virus entry in host cells. The potential T- and B-cell
epitopes were chosen using computational programs based on
hydrophobicity, solvent accessibility and secondary structure.
The T-cell epitopes were synthesized in order to allow a
possible secondary structure longer than the predicted
sequences for gB493–509 gB577–599 epitopes and gD119–140
gD215–234. B-cell epitopes were synthesized in short sequences
to avoid synthetic diﬃculty. In fact the Na terminal positions
can be hindered by steric constrain of previously coupled
peptides. Peptide conjugates were obtained using a combination
of diﬀerent peptide solid phase strategies. Branched polypeptide
conjugates were obtained using a convergent strategy. An
advantage of the convergent strategy is chemical unambiguity
because the protected peptide segments and the branching unit
used in coupling reactions are puriﬁed prior to the reaction,
thereby limiting the range of by-products and facilitating
puriﬁcation. Using this strategy we were able to conjugate
three diﬀerent epitopes on the LCP core.
Stimulating U937 and RAW 264.7 cells with LCP constructs
induced signiﬁcant MAPKs activation. This pathway of signal
transmission co-operates with other pathways of gene activa-
tion to the synthesis of IL-6, IL-8 or MIP-2 and TNF-a. Many
viruses can use as speciﬁc receptors, macrophage or lympho-
cyte surface molecules modifying the antiviral functions of
these cells.52,53 Wang et al. demonstrated that a SARS-surface
viral protein stimulates the production of TNF-a and IL-6.55
These results provide evidence that the LCP constructs
initiate macrophages activation, leading to the production of
pro-inﬂammatory cytokines. LCP complexed with immuno-
dominating viral peptides enhances the signal transduction
pathways with a predominant activation of the ERK1/2 path-
way. A combination of Lys3-LCP with non-covalent mixtures
of both gB and gD has been analysed in signal transduction
pathway assays to evaluate cytokine production showing
results that almost superimpose results obtained using the
Lys3-LCP construct alone, thus conﬁrming the relevance of
the covalent link between peptide epitopes and the lipidic
construct to obtain optimal activation.
The cells implicated in the immunological response contain
a large repertoire of receptors which are responsible for sur-
face interaction with microorganisms and their components.
These cell surface interactions lead to activation of several
signal transmission pathways which induce cytokine synthesis
and release, therefore, our results show that LCP constructs
bearing HSV gB or gD derived peptides represent a promising
system for the production of eﬃcient immunogens.
Therefore, the idea of selecting the best HSV epitopes from
gB and gD for the development of a multivalent (LCP) vaccine
might be of great beneﬁt and a practical way to generate
broader multiepitope protective T-cell responses.
Fig. 7 Analysis of the eﬀects of the SB203580 (SB; p38 inhibitor),
PD-098059 (PD; ERK1/2 inhibitor) or L-JNKI1 (JNK inhibitor) on
IL-6, IL-8 or MIP-2 and TNF-a release induced in U937 cells (A) and
RAW 264.7 cells (B). The results shown are the average of three
independent experiments, and the error bars indicate the standard
errors of the means.
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Abbreviations
APC Antigen presenting cells
Boc tert-Butyloxycarbonyl
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
DCM Dichloromethane
DIEA Diisopropylethylamine
DMF N,N-Dimethylformamide
ERK Extracellular signal Regulated protein Kinase
FACE Fast activated cell-based
ELISA INT, Tetrazolium salt
HATU 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetra-
methyluronium hexaﬂuorophosphate
HOBt 1-Hydroxy-1,2,3-benzotriazole
HSV-1 Herpes simplex virus type 1
HSV-2 Herpes simplex virus type 2
IL-6 Interleukin-6
IL-8 Interleukin-8
INT (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phenyl-
2H-tetrazolium chloride)
JNK Jun NH2-terminal kinase
LAL Limulus amoebocyte lysate
LDH Lactate dehydrogenase
MAPK Mitogen-activated protein kinase
MIP-2 Macrophage inﬂammatory peptide-2
PAM Phenylacetamidomethyl-resin
Pam3Cys N-Palmitoyl-S-[2,3-bis(palmitoyloxy-(2R,S)-
propyl]-(R)-cysteine
PyBOP Benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexaﬂuorophosphate
RP-HPLC Reverse-phase high-pressure liquid
chromatography
RPMI 1640 Roswell Park Memorial Institute medium
SPPS Solid phase peptide synthesis
TFA Triﬂuoroacetic acid
TFMSA Triﬂuoromethanesulfonic acid
TIS Triisopropylsilane
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